Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285–1300 (2018).
Miller, I. F., Becker, A. D., Grenfell, B. T. & Metcalf, C. J. E. Disease and healthcare burden of COVID-19 in the United States. Nat. Med. 26, 1212–1217 (2020).
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G. & Schultz-Cherry, S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. Nat. Rev. Microbiol. 19, 425–441 (2021).
Fahy, J. V. & Dickey, B. F. Airway mucus function and dysfunction. N. Engl. J. Med. 363, 2233–2247 (2010).
Ostedgaard, L. S. et al. Gel-forming mucins form distinct morphologic structures in airways. Proc. Natl Acad. Sci. USA 114, 6842–6847 (2017).
Cho, H. Y. et al. Role for mucin-5AC in upper and lower airway pathogenesis in mice. Toxicol. Pathol. 49, 1077–1099 (2021).
Roy, M. G. et al. Muc5b is required for airway defence. Nature 505, 412–416 (2014).
Zanin, M., Baviskar, P., Webster, R. & Webby, R. The interaction between respiratory pathogens and mucus. Cell Host Microbe 19, 159–168 (2016).
Russell, C. J., Hu, M. & Okda, F. A. Influenza hemagglutinin protein stability, activation, and pandemic risk. Trends Microbiol. 26, 841–853 (2018).
Vahey, M. D. & Fletcher, D. A. Influenza A virus surface proteins are organized to help penetrate host mucus. eLife 8, e43764 (2019).
Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A. & Klenk, H. D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78, 12665–12667 (2004).
Walsh, P. S. et al. Association of early oseltamivir with improved outcomes in hospitalized children with influenza, 2007-2020. JAMA Pediatr. 176, e223261 (2022).
Wu, C. T. et al. SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. Cell 186, 112–130 e120 (2023).
Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446–448 (1993).
Desmyter, A. et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 3, 803–811 (1996).
Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775–797 (2013).
Kang, T. H. & Jung, S. T. Boosting therapeutic potency of antibodies by taming Fc domain functions. Exp. Mol. Med. 51, 1–9 (2019).
Chen, Z. S. et al. Influenza A virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection. Nat. Commun. 16, 432 (2025).
Hanke, L. et al. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat. Commun. 13, 155 (2022).
Berger, J. T., Voynow, J. A., Peters, K. W. & Rose, M. C. Respiratory carcinoma cell lines. MUC genes and glycoconjugates. Am. J. Respir. Cell Mol. Biol. 20, 500–510 (1999).
Kreft, M. E. et al. The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. Eur. J. Pharm. Sci. 69, 1–9 (2015).
Malaker, S. A. et al. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc. Natl Acad. Sci. USA 116, 7278–7287 (2019).
Alevy, Y. G. et al. IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. J. Clin. Invest. 122, 4555–4568 (2012).
Muyldermans, S. A guide to: generation and design of nanobodies. FEBS J. 288, 2084–2102 (2021).
McMahon, C. et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat. Struct. Mol. Biol. 25, 289–296 (2018).
Zhang, Y. et al. Hedgehog pathway activation through nanobody-mediated conformational blockade of the patched sterol conduit. Proc. Natl Acad. Sci. USA 117, 28838–28846 (2020).
Brown, R. L., Sequeira, R. P. & Clarke, T. B. The microbiota protects against respiratory infection via GM-CSF signaling. Nat. Commun. 8, 1512 (2017).
Jordan, C. K. I. & Clarke, T. B. How does the microbiota control systemic innate immunity?. Trends Immunol. 45, 94–102 (2024).
Blazejewska, P. et al. Pathogenicity of different PR8 influenza A virus variants in mice is determined by both viral and host factors. Virology 412, 36–45 (2011).
Port, J. R. et al. SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters. Nat. Commun. 12, 4985 (2021).
Morens, D. M., Taubenberger, J. K. & Fauci, A. S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe 31, 146–157 (2023).
Lavelle, E. C. & Ward, R. W. Mucosal vaccines—fortifying the frontiers. Nat. Rev. Immunol. 22, 236–250 (2022).
McMahan, K. et al. Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques. Nature 626, 385–391 (2024).
Ye, T. et al. Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization. Nature 624, 630–638 (2023).
Lillehoj, E. P., Kato, K., Lu, W. & Kim, K. C. Cellular and molecular biology of airway mucins. Int. Rev. Cell Mol. Biol. 303, 139–202 (2013).
Ehre, C. et al. Overexpressing mouse model demonstrates the protective role of Muc5ac in the lungs. Proc. Natl Acad. Sci. USA 109, 16528–16533 (2012).
Guo, Y. et al. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm. Sin B 11, 2565–2584 (2021).
Keller, L. A., Merkel, O. & Popp, A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv. Transl. Res. 12, 735–757 (2022).
Famta, P. et al. Albumin-hitchhiking: fostering the pharmacokinetics and anticancer therapeutics. J. Control. Release 353, 166–185 (2023).
Hu, H., Quintana, J., Weissleder, R., Parangi, S. & Miller, M. Deciphering albumin-directed drug delivery by imaging. Adv. Drug Deliv. Rev. 185, 114237 (2022).
Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361–379 (2023).
Halfmann, P. J. et al. Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. Cell Rep. 39, 110688 (2022).
Dewald, F. et al. Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients. Nat. Commun. 14, 2835 (2023).
Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027–1037 (2022).
Shin, M. D. et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 15, 646–655 (2020).
Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12, 513 (2020).
Harcourt, J. et al. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg. Infect. Dis. 26, 1266–1273 (2020).
O’Donnell, K. L. et al. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. EBioMedicine 73, 103675 (2021).
van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578–582 (2020).
Meyerholz, D. K. & Beck, A. P. Histopathologic evaluation and scoring of viral lung infection. Methods Mol. Biol. 2099, 205–220 (2020).